Paradigm Biopharmaceuticals Limited (ASX: PAR) has announced the conversion of convertible notes into ordinary fully paid shares, with 9,437,229 new shares issued on 17 July 2026. The conversion stems from the exercise of 900,000 convertible notes (PARAAD) that have been converted into ordinary shares at an issue price of AUD 0.15 per security. The move increases the company’s quoted equity capital and reflects the ongoing conversion of debt-like instruments into equity as part of the company’s capital management strategy.
Key Points
- Paradigm Biopharmaceuticals Limited (PAR) has lodged an application for quotation of 9,437,229 ordinary fully paid shares issued on 17 July 2026
- The new shares resulted from the conversion of 900,000 convertible notes (PARAAD) into ordinary shares at an issue price of AUD 0.15 per share
- Following this quotation, PAR will have 594,280,824 quoted ordinary fully paid shares on issue
- The company continues to maintain unquoted securities including 11,127,100 performance rights, 3,000,000 options expiring 30 June 2027, and 7,547,185 remaining convertible notes
Convertible Note Conversion Mechanics and Timeline
Paradigm Biopharmaceuticals has completed the conversion of convertible notes into ordinary shares as part of its ongoing capital structure management. The company announced that 900,000 convertible notes, previously classified as PARAAD securities, have been converted into ordinary fully paid shares. The conversion process commenced at an unspecified date and concluded on 17 February 2026, with the resulting shares issued and applied for quotation on 17 July 2026. This timeline suggests a period of several months between the final conversion date and the formal ASX quotation application, which is consistent with standard regulatory processing periods for securities listings.
The conversion was completed at an issue price of AUD 0.15 per ordinary share, resulting in the creation of 9,437,229 new ordinary fully paid shares. The announcement confirms that these new securities rank equally in all respects from their issue date with the existing issued ordinary shares in that class, meaning they carry identical rights and entitlements to previously issued ordinary shares. This parity ensures that holders of the newly issued shares have no preferential or disadvantaged position relative to other ordinary shareholders, maintaining consistency across the shareholder base.
Impact on Paradigm Biopharmaceuticals’ Issued Capital Structure
Following the quotation of these 9,437,229 ordinary shares, Paradigm Biopharmaceuticals’ total quoted issued capital will comprise 594,280,824 ordinary fully paid shares and 117,069,101 options expiring 1 December 2026. This represents a significant portion of the company’s total equity structure and reflects the company’s reliance on share issuance as a mechanism for capital raising and debt conversion. The expansion of the quoted share capital by approximately 1.6 percent through this single conversion demonstrates the ongoing nature of the company’s capital management activities and the conversion of convertible instruments into equity.
Beyond the quoted securities, Paradigm Biopharmaceuticals maintains a substantial portfolio of unquoted securities that remain available for future conversion or exercise. The company has 11,127,100 unquoted performance rights, 3,000,000 options expiring 30 June 2027 with an exercise price of AUD 0.65, 151,293 options expiring 11 February 2028 with an exercise price of AUD 1.00, and 7,547,185 remaining convertible notes (PARAAD). The presence of this unquoted securities base suggests the company has additional conversion and exercise events that may occur in the future, potentially affecting the capital structure further.
Remaining Convertible Notes and Ongoing Conversion Potential
Although 900,000 convertible notes have been converted in this transaction, Paradigm Biopharmaceuticals still maintains 7,547,185 convertible notes (PARAAD) on issue as unquoted securities. This substantial remaining balance indicates that the current conversion represents only a partial exercise of the company’s convertible debt instruments, and additional conversions may be triggered in future periods. The retention of these convertible notes provides flexibility for the company and its security holders, as the conversion terms and conditions may allow for staged or discretionary conversion depending on the specific terms of the instrument documentation.
The presence of both converted and unconverted convertible notes within the company’s capital structure reflects typical biopharmaceutical company financing practices, where convertible instruments serve as a bridge between debt and equity financing. The staged conversion of these instruments allows the company to manage its capital structure progressively while potentially taking advantage of market conditions and company milestones. Investors monitoring Paradigm Biopharmaceuticals may wish to track the conversion of the remaining 7.5 million convertible notes, as such conversions could materially affect the company’s equity structure and share dilution profile.
Performance Rights and Unquoted Options Composition
In addition to the convertible notes, Paradigm Biopharmaceuticals maintains a significant allocation of performance rights and options that remain unquoted. The company has issued 11,127,100 performance rights, which typically represent conditional grants of shares subject to the achievement of specified performance milestones or time-based vesting conditions. These instruments are commonly used in biopharmaceutical companies as part of employee incentive schemes and management compensation arrangements. The absence of a disclosed exercise price or conversion mechanism for the performance rights suggests they may be subject to vesting conditions rather than financial exercise thresholds.
The company also maintains two separate classes of unquoted options with different expiration dates and exercise prices. The 3,000,000 options expiring 30 June 2027 carry an exercise price of AUD 0.65 per share, while the 151,293 options expiring 11 February 2028 have an exercise price of AUD 1.00 per share. The existence of these in-the-money or near-the-money options (depending on the current share price) represents potential future dilution to existing shareholders if exercised. The different exercise prices may reflect options issued at different times or as part of different financing or incentive arrangements within the company.
Biopharmaceutical Sector Context and Capital Raising Practices
Paradigm Biopharmaceuticals operates within the biopharmaceutical sector, an industry characterised by high research and development costs, long product development timelines, and significant capital requirements before revenue generation. Convertible notes and other hybrid securities are commonly employed in this sector as a mechanism for raising capital while deferring the immediate dilution associated with equity issuance. The conversion of these instruments into ordinary shares typically occurs when the company reaches certain milestones, valuations, or time-based triggers, allowing investors and the company to benefit from value creation between issuance and conversion.
The use of performance rights and options within Paradigm Biopharmaceuticals’ capital structure is also typical of biopharmaceutical companies seeking to align management and employee interests with long-term value creation. These instruments allow companies to defer cash compensation and tie rewards to the achievement of specific development, regulatory, or commercial milestones. The presence of multiple option classes with varying exercise prices and expiration dates suggests a layered incentive structure designed to motivate different cohorts of employees or contractors over different timeframes aligned with the company’s strategic objectives.
Currency Denomination and Pricing Framework
The conversion of Paradigm Biopharmaceuticals’ convertible notes into ordinary shares occurred at an issue price denominated in Australian dollars (AUD 0.15 per share), reflecting the company’s ASX listing and primary capital raising in Australian currency. This AUD denomination is consistent with the company’s Australian incorporation and ASX quotation status. The specific issue price of AUD 0.15 per share may reflect the conversion terms embedded within the original convertible note documentation, which typically specifies either a fixed conversion price or a formula for determining the conversion price at the time of exercise.
The consistency of pricing across convertible note conversions and ordinary share issuances simplifies the company’s capital management and ensures transparency in the conversion process. Investors evaluating Paradigm Biopharmaceuticals should note that the issue price of AUD 0.15 per share at the time of this conversion may provide context for the relative valuation of the company at different points in its financing history. Understanding the price points at which the company has issued or converted securities can provide insight into the company’s valuation progression and the relative value attributed to the company by different investor cohorts over time.
ASX Listing Rules Compliance and Application Process
Paradigm Biopharmaceuticals’ application for quotation of the 9,437,229 ordinary shares has been submitted in accordance with ASX Listing Rules, specifically using the Appendix 2A form designed for applications for quotation of securities. The company’s application confirms that the new ordinary shares result from the conversion of existing convertible securities rather than representing an entirely new class of security. This classification is significant under ASX Listing Rules because it means the company is not seeking approval for a new security type but rather for the quotation of additional securities in an existing class that already has quoted status on the exchange.
The Appendix 2A application process requires the company to disclose detailed information about the securities being quoted, including the number of securities, issue date, issue price, and information about the issued capital following quotation. By applying for quotation of these securities, Paradigm Biopharmaceuticals ensures that the newly converted shares are formally recognised on the ASX and can be freely traded by holders. This process provides certainty to investors holding the newly converted shares and ensures that the company’s share register accurately reflects the expanded equity capital base following the conversion event.
Shareholder Dilution and Capitalization Implications
The issuance of 9,437,229 new ordinary shares through the conversion of convertible notes represents a material increase in Paradigm Biopharmaceuticals’ quoted share capital. While the exact percentage dilution to existing shareholders depends on the shareholder composition and holdings at the time of conversion, the addition of nearly 9.4 million new shares to a total quoted capital of 594.3 million shares represents an increase of approximately 1.6 percent in the quoted share count. This dilution is typical of biopharmaceutical companies that regularly convert convertible instruments into equity as part of their capital management strategy.
The timing and impact of this dilution would have been embedded within the terms of the original convertible note issuance, meaning existing shareholders at the time of convertible note issuance would have contemplated this potential dilution when evaluating their investment. However, for shareholders who acquired shares subsequent to the issuance of the convertible notes, this conversion represents an unexpected increase in share count and a corresponding decrease in their percentage ownership of the company. Understanding the company’s outstanding convertible securities and their conversion terms is therefore essential for investors seeking to evaluate potential future dilution impacts on their shareholdings.
Next Steps and Monitoring for Investors
Following the ASX’s acceptance of Paradigm Biopharmaceuticals’ application for quotation, the 9,437,229 newly converted ordinary shares will be available for trading on the ASX alongside the company’s existing ordinary shares. The quotation of these securities marks the completion of the conversion process for this particular tranche of convertible notes, though the company retains the right to convert its remaining 7,547,185 convertible notes at some future date. Investors should monitor Paradigm Biopharmaceuticals’ quarterly reports and substantial shareholder notices for information about any further conversions or exercises of the company’s outstanding convertible securities and options.
The company’s ongoing management of its capital structure, particularly the staged conversion of convertible instruments into equity, will continue to be relevant to shareholder value analysis and dilution assessments. Investors may wish to track the exercise of the 3,000,000 options expiring 30 June 2027 and the vesting of the 11,127,100 performance rights, as these events could trigger additional share issuances and further dilution. Additionally, monitoring the company’s financial performance and strategic milestones will provide context for understanding the business justifications behind the company’s capital structure decisions and the timing of securities conversions.